Alterity Therapeutics (ATHE) Cash from Discontinued Operations (2009 - 2016)
Alterity Therapeutics (ATHE) posted quarterly Cash from Discontinued Operations of 465813.11 for Q4 2016, up 91.23% year-over-year from 243590.35 in Q1 2016, and up 91.23% quarter-over-quarter from 5310262.34 in Q4 2015.
Alterity Therapeutics (ATHE) Cash from Discontinued Operations (2009 - 2016) Analysis & Trends
Alterity Therapeutics' Cash from Discontinued Operations history runs 6 years deep, the most recent figure standing at 465813.11 for Q4 2016.
- In Q4 2016, Cash from Discontinued Operations rose 91.23% year-over-year to 465813.11; the TTM figure through Dec 2016 stood at 6933575121472.9 (changed 0.0% YoY), while the FY2024 annual figure was 12605824.0, changed N/A from the prior year.
- Cash from Discontinued Operations for Q4 2016 stood at 465813.11, up from 5310262.34 in the prior quarter.
- The five-year high for Cash from Discontinued Operations was 465813.11 in Q4 2016, with the low at 6933562150191.48 in Q2 2014.
- The 3-year median for Cash from Discontinued Operations is 6252734.16 (2015), against an average of 1733393780368.22.
- The sharpest annual moves came in 2015 and 2016: Cash from Discontinued Operations grew 26.2% in 2015, then soared 91.23% in 2016.
- Alterity Therapeutics' Cash from Discontinued Operations stood at 7195205.97 in 2014, then increased by 26.2% to 5310262.34 in 2015, then soared by 91.23% to 465813.11 in 2016.
- Business Quant data shows ATHE's Cash from Discontinued Operations at 465813.11 in Q4 2016, 5310262.34 in Q4 2015, and 7195205.97 in Q4 2014.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Discontinued Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Alterity Therapeutics | 48.56 Mn | 16.26 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2016 | -465,813.11 |
| Dec 31, 2016 | -465,813.11 |
| Dec 31, 2015 | -5.31 Mn |
| Dec 31, 2015 | -5.31 Mn |
| Dec 31, 2014 | -7.20 Mn |
| Dec 31, 2014 | -7.20 Mn |
| Jun 30, 2014 | -6,933.56 Bn |
| Jun 30, 2014 | -6,933.56 Bn |
| Dec 31, 2011 | -3.94 Mn |
| Dec 31, 2011 | -3.94 Mn |
| Dec 31, 2010 | -3.29 Mn |
| Dec 31, 2010 | -3.29 Mn |
| Dec 31, 2009 | -1.60 Mn |
| Dec 31, 2009 | -1.60 Mn |